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ABSTRACT
Purpose Evaluate fundamental parameters that dictate the
effectiveness of drug loading.
Methods A model water-soluble drug lacking ionizable
groups, pirfenidone (PFD), was encapsulated through
nanoprecipitation in poly(ethylene glycol)-poly(lactic acid)
(PEG-PLA)-poly(lactic-co-glycolic acid) (PLGA) NPs.
Firstly, the thermodynamic parameters predicting drug-
polymer miscibility were determined to assess the system’s
suitability. Then, the encapsulation was evaluated experi-
mentally by two different techniques, bulk and microfluidic
(MF) nanoprecipitation. Additionally, the number of mol-
ecules that fit in a particle core were calculated and the
loading determined experimentally for different core sizes.
Lastly, the effect of co-encapsulation of α-lipoic acid (LA),
a drug with complementary therapeutic effects and en-
hanced lipophilicity, was evaluated.
Results The thermodynamic miscibility parameters predicted
a good suitability of the selected system. MF manufacturing
enhanced the encapsulation efficiency by 60–90% and
achieved a 2-fold higher NP cellular uptake. Considering spa-
tial constrictions for drug encapsulation and increasing the
size of the PLGA core the number of PFD molecules per
NP was raised from under 500 to up to 2000. More so, the
co-encapsulation of LA increased the number of drug mole-
cules per particle by 96%, with no interference with the re-
lease profile.
Conclusions Thermodynamic, spatial and methodological
parameters should be considered to optimize drug
encapsulation.
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ABBREVIATIONS
χsp Flory-Huggins interaction parameter
FRR Flow rate ratio
LA α-lipoic acid
PEG Poly(ethylene glycol)
PFD Pirfenidone
PLA Poly(lactic acid)
PLGA Poly(lactic-co-glycolic acid)
MF Microfluidic
ΔHMT Mixing enthalpy obtained from the total
solubility parameters
ΔHM Mixing enthalpy obtained from the partial
solubility parameters
NPs Nanoparticles
δ Solubility parameter
TFR Total flow rate
INTRODUCTION
Nanoprecipitation (1), or solvent displacement, is a frequently
used technique for the preparation of therapeutic polymer
nanoparticles (NPs), as it is a simple, clean, and versatile ap-
proach (2). More so, it enables drug encapsulation without
requiring additional steps, such as covalently coupling the
drug to structural particle components.
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There are several elements that to some extent determine
the success of a nanoprecipitation-mediated drug encapsula-
tion, such as the physicochemical characteristics of the selected
drug. As this technique involves the addition of a small volume
of organic polymer phase into a large volume of aqueous phase,
it has mostly been exploited for the encapsulation of lipophilic
drugs that have little to no water solubility. Its application to
water-soluble drugs is often inefficient, but can be improved to
some extent by modulating the pH value of the water phase
(3–5) or promoting electrostatic interaction with excipients (4).
Alternatively, some authors have resulted to modify the drug
molecule itself (6), or released it from its salt form (2), for which
doxorubicin is a common example (7). However, these
approaches are not universally applicable. For the former the
presence of ionizable groups is a mandatory requirement and
the latter may not be a feasible option due to the additional
regulatory burdens associated with changing a drug’s structure.
More so, there is a lack of research regarding the encapsulation
through nanoprecipitation of water-soluble molecules that lack
the aforementioned criteria.
An additional element that has an impact on drug encap-
sulation is the thermodynamic compatibility, i.e. miscibility, of
the drug and particle-forming polymers. Therefore, thermo-
dynamic parameters such as the Flory-Huggins interaction
parameter (χsp), or the solubility parameters (δ) are frequently
used to assess drug-polymer miscibility (8). However, there are
other elements that can determine the successful encapsula-
tion of a drug in a selected particle system, such as dimensional
restrictions, the used nanoprecipitation method or the pres-
ence of a co-encapsulated drug molecule.
Therefore, the goal of this study was to encapsulate
through nanoprecipitation a partially water-soluble drug lack-
ing ionizable groups and evaluate different parameters dictat-
ing the drug loading.
As a drug model for our purposes we selected pirfenidone
(PFD) (Fig. 1). PFD is a small molecule drug, with a log P =
2.14. Therefore, it would be initially considered a good can-
didate for encapsulation through nanoprecipitation.
However, it is soluble in water up to 2 mg/mL, which is
exceedingly high for this technique, due to the large volumes
of water phase being used.
PFD is an antifibrotic agent, approved for the treatment of
idiopathic pulmonary fibrosis (9). Additionally, recent studies
showed its potential for the treatment of diabetic kidney dis-
ease (10,11) and glomerulosclerosis (12). However, it has a
considerable plasma protein binding (50%) and fast elimina-
tion half-life (2.4 h), which requires a large oral dose intake (>
2 g/day) to achieve therapeutic effects (13). This elevated daily
intake prompts considerable gastrointestinal side effects which
contribute to therapy discontinuation by a large number of
patients (11,14). Therefore, it is an excellent candidate that
would benefit from incorporation in a nanoparticulate system.
Over the past years PFD has been encapsulated in PLGANPs
by the emulsion solvent evaporation method for the treatment
of pulmonary fibrosis (15) and corneal wounds (16), in
chitosan-alginate nanocarriers through the pre-gelation meth-
od for transdermal delivery (17) and in liquid crystalline nano-
particles (18). However, it has never been encapsulated before
by means of nanoprecipitation, which would considerably
ease NP preparation and allow for simple cost-effective
upscaling and reproducible results (19).
For our systematic investigation of the PFD encapsulation
we relied on well-established poly(ethylene glycol)-poly(lactic
acid) (PEG-PLA) block copolymer NPs (20) with a poly(lactic-
coglycolic acid) (PLGA)-stabilized core (Fig. 1). Such particles
are known for their good biocompatibility and highly tunable
composition. Additionally, by modifying the PEG end-groups
with ligands the particles can be targeted to receptors on the
cellular membrane to increase their specificity (21). To evalu-
ate the suitability of our particle system for the encapsulation
of PFD we firstly estimated the compatibility of PFD with the
particle-forming polymers through the calculation of thermo-
dynamic miscibility parameters. Then, we prepared the NPs
through two different nanoprecipitation techniques, bulk and
microfluidic (MF) manufacturing, and assessed the drug load-
ing. More so, we investigated the influence of the two different
approaches on the NP characteristics and their interaction at
cellular level. Additionally, we evaluated the spatial constrain
on drug loading by calculating the number of molecules that
can fit in a single NP core and experimentally determined the
influence of this parameter by preparing particles with larger
cores. Finally, we investigated the effect of introducing an
Fig. 1 Encapsulation of PFD in
block copolymer NPs. Particles are
prepared through nanoprecipitation
of organic mixtures of PEG-PLA,
PLGA and the drug in aqueous
medium.
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additional drug molecule in the formulation, α-lipoic acid
(LA), on PFD encapsulation.
MATERIALS AND METHODS
Materials
Methoxy and carboxylic acid end-functionalized PEG
(MeO-PEG5k-OH and COOH-PEG5k-OH) with a molec-
ular weight of 5000 Da were purchased from JenKem
Technology USA Inc. (Allen, TX, USA). PFD was
obtained from MedChem Express (Sollentuna, Sweden).
Dulbecco’s phosphate-buffered saline (DPBS) was pur-
chased from Thermo Fisher Scientific (Waltham, MA,
USA). LA, PLGA with a molecular weight of 13.4 kDa,
and all other reagents and chemicals in analytical grade
were purchased from Sigma Aldrich (Taufkirchen,
Germany). Ultrapure water for particle preparation was
obtained from a Millipore Milli-Q water purification sys-
tem (Billerica, MA, USA).
Compatibility of Drug and Particle-Assembling
Polymers
To predict the miscibility of particle-forming polymers
with either PFD or LA, different thermodynamic param-
eters were calculated. To that end, an ideal particle poly-
mer distribution was assumed where PEG conforms the
shell, PLGA the core, and PLA is situated at the core-shell
interphase. The interference of concurring NP polymers
in the miscibility was not taken into consideration. The
total solubility parameters (δ) were obtained from litera-
ture values for the polymers (PEG (24.0 MPa1/2) (22),
PLA (22.0 MPa1/2) (22) and PLGA (22.3 MPa1/2) (23)),
and calculated for PFD and LA using the partial solubility
parameters after Krevelen and Nijenhuis (24) determined
by the group contributions methods using Eq. 1–3. δd, δp,
δh are the partial solubility parameters associated with the
dispersion forces, the polar interactions and the hydrogen
bonding components, respectively.
δd ¼ ∑FdiV ð1Þ
δp ¼
∑F 2pi
 1=2
V
ð2Þ
δh ¼ ∑EhiV
 1=2 ð3Þ
The estimation of the molecular volume of PFD
(V = 119 cm3) and LA (V= 144 cm3) was done by the group
contribution methods after Fedors (25). The total solubility
parameters were determined using Eq. 4 (24).
δ2 ¼ δ2d þ δ2p þ δ2h ð4Þ
The differences in solubility parameters (Δδ, Δδd, Δδp,
Δδh) were calculated by subtracting the polymer’s from
the drug’s solubility parameter. The mixing enthalpy cal-
culated from the total- or partial solubility parameters
(ΔHMT and ΔHM, respectively) was determined according
to Eq. 5 (26) and 6 (27), where Φ1 and Φ2 and δ1 and δ2
represent the volume fractions and the solubility parame-
ters of the drug and polymer, respectively.
ΔHMT ¼ ϕ1ϕ2 δdrug−δpolymer
 2 ð5Þ
ΔHM ¼ ϕ1ϕ2 δd1−δd2ð Þ2 þ δp1−δp2
 2h þ δh1−δh2ð Þ2
i
ð6Þ
The Flory-Huggins interaction parameter (χsp) was calcu-
lated with the Hildebrand-Scatchard equation (Eq. 7) using
the obtained total solubility parameters.
χsp ¼ δ1−δ2ð Þ2
V drug
RT
ð7Þ
Polymer Synthesis
Block copolymers (PEG5k-PLA10k) with different PEG-end
functionalization (MeO, or COOH) were synthesized after
Qian et al. (28) with slight modifications as previously de-
scribed by our group (29). In brief, for the ring opening poly-
merization of cyclic 3,6-dimethyl-1,4-dioxane-2,5-dione (lac-
tide), MeO-PEG5k-OH and COOH-PEG5k-OH were used
as macroinitiators using 1,8-diazabicyclo[5.4.0]undec-7-ene
(DBU) as a catalyst. As products, MeO-PEG5k-PLA10 and
COOH-PEG5k-PLA10k were obtained, for non-targeted and
targeted NP preparation, respectively (please refer to supple-
mentary methods for ligand modification of the polymers).
Particle Preparation Via Bulk or Microfluidic
Nanoprecipitation
Block copolymer NPs were prepared through nanoprecipita-
tion of PEG5k-PLA10k and PLGA13.4k polymer mixtures. To
that end, and if not indicated otherwise, PEG-PLA and PLGA
were mixed at a 70:30 mass ratio in acetonitrile (ACN) to a
final polymer concentration of 10 mg/mL (1 mL). For drug-
loaded particles, different amounts of PFD ranging from
25 μg to 10 mg (1–600-fold molar excess to PLGA) were
added to the polymer mixture. Afterwards, for bulk nanopre-
cipitation, they were pipetted in stirring sterile filtrated
Millipore water (5 mL) at a 1:5 organic to aqueous phase ratio
to a polymer concentration of 2 mg/mL.
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For MF manufacturing, the particles were prepared using
the NanoAssemblr™ Benchtop (Precision NanoSystems Inc.,
Vancouver, Canada). Process parameters were controlled us-
ing the NanoAssemblr™ controller software (v1.09). If not
noted otherwise the particles were prepared at a total flow
rate (TFR) of 2 mL/min and a flow rate ratio (FRR) of 1:5
organic to water phase. To investigate the effect on drug load-
ing of the different microfluidic parameters, the TFR (2–
12 mL/min) and the FRR (1:1–1:10) were varied.
For both preparation techniques, immediately after prep-
aration, particles were diluted to 20 mL with Millipore water
and purified and concentrated through ultracentrifugation
with a 30-kDa molecular weight cutoff Microsep advance
centrifugal device (Pall corporation, NY, USA) at 959 x g for
20 min. Purification from free or adsorbed drug was per-
formed through thoroughly washing the NPs with Millipore
water and ultracentrifugation, as described above (2×).
Particle Characterization
The particle size was determined through dynamic light scat-
tering (DLS) using a ZetaSizer Nano ZS. The device was
equipped with a 633 nm He-Ne laser at a backscatter angle
of 173° (Malvern Instruments GmbG, Lappersdorf, Germany).
Measurements were performed at 25°C using Millipore water
as dispersing medium and a NP concentration of 1 mg/mL.
The measurement position was set at 4.65 mm and the data
was recorded with Malvern Zetasizer software 7.11 (Malvern
Instruments, Worcestershire, United Kingdom).
The particle PEG content was determined using a colori-
metric iodine complexing assay (30) as previously described by
our group (29).
The NPmass concentration was determined gravimetrical-
ly after lyophilization and the PFD content was measured
photometrically after particle disruption in ACN at 300 nm
using a FLUOStar Omega microplate reader (BMG Labtech,
Ortenberg, Germany). The NP molar concentration
(PNC) was calculated using Eq. 8 where m is the NP mass
determined gravimetrically after lyophilization, ρNP is the
density of the particles (1.25 g/cm3) (31), dh is the hydrody-
namic diameter of the NPs determined through DLS, NA is
the Avogadro number, and V the volume of the samples.
PNC ¼ m
ρNP
4
3
π
dh
2
 3 x
1
N A V
ð8Þ
The encapsulation efficiency (EE) was determined using Eq.
9,where mE is the quantified mass of entrapped drug, and mT is
the total mass of drug added initially to the formulation.
EE %ð Þ ¼ mE
mT
x 100 ð9Þ
The loading capacity (LC) was determined through Eq. 10,
where MT is the total mass of the particle formulation.
LC %ð Þ ¼ mE
MT
x 100 ð10Þ
The number of drug molecules per NP was calculated by
dividing the molar concentration of the drug by the molar
concentration of the NPs determined as described above.
Determination of the Spatial Restriction of PFD
Loading
To determine the number of molecules that fit inside a NP,
the volume of the particle core was estimated. To that end, the
mean NP size was used as a starting point. For the calculation
it was considered that the PLA is located at the core-shell
interface and that the PLGA and PEG form the core and
shell, respectively. To estimate the core size, first the confor-
mation of the PEG on the particle surface was investigated
using the Flory radius (RF) (32). When the distance between
polymer chains on a particle surface is smaller than the RF,
they assume an extended brush conformation. Otherwise,
they take a folded mushroom configuration. The RF can be
calculated using Eq. 11, where α is the length of a PEGmono-
mer (0.278–0.358 nm) (33) and N is the number of monomers
in one molecule (each monomer has the molecular weight of
44 g/mol).
RF ¼ αN 35 ð11Þ
The surface (S) that is taken by the polymers on the particle
surface can be calculated after Gref et al. (34) using Eq. 12.
MPEG represents the molecular weight of the PEG, and f is the
mass fraction of PEG in the PEG-PLA blends. The S can be
used to determine the distance between polymers (D) on the
particle surface using Eq. 13 (34).
S ¼ 6 MPEG
dh N A f ρNP
ð12Þ
D ¼ 2 S
π
 1
2
ð13Þ
The length in nm of a PEG brush can be calculated by
multiplying themonomer length α= 0.35 nm byN. This value
was subtracted twice from the dh of the NP to obtain the
diameter of the particle core (dc). The volume of the core
(Vcore) was calculated assuming a spherical shape after Eq. 14,
where rc is the calculated radius of the particle core (dc/2).
Vcore ¼ 4
3
πr3c ð14Þ
The estimation of the molecular volume of PFD (Vdrug =
0.2 nm3) was conducted using the group contribution methods
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after Fedors (25). The number of drug molecules that are able
to fit inside a single particle core were calculated through Eq.
15, assuming the maximal packing efficiency of poly-sized
spheres (90%) (35), a spherical molecule shape and an even
drug distribution among all the particles.
Drug molecules per NP ¼ V core
V drug
x 0:9 ð15Þ
In order to prepare particles with increasing PLGA core
sizes, the PLGA content of the formulations was increased.
Particles with a PEG-PLA to PLGA mass ratio of 70:30,
60:40, 50:50 and 40:60 were prepared to a total final polymer
concentration of 10 mg/mL, as described above. NPs were
prepared through bulk nanoprecipitation and an initial PFD
mass of 25 μg, as described above.
Co-Encapsulation of LA
For the co-encapsulation of LA and PFD, the NPs were pre-
pared as described above. LA and PFD were simultaneously
added to the organic polymer mixture prior to particle prep-
aration. The PFD to LA molar ratio was varied to determine
the ideal particle composition. Additionally, the initial PFD
amount was set to 2 mg and LA in a molar excess (ranging
from 0.1 to 3.5) was added to the different formulations. As a
control, NPs only encapsulating LA at the same concentra-
tions added to the PFD-containing formulations were pre-
pared. As an additional control the molar excess of LA added
was replaced by the same molar excess of PFD. The PFD or
LA content in the formulations was determined photometri-
cally after particle lyophilization and disruption in ACN at
300 or 334 nm, respectively, using a FLUOStar Omega
microplate reader (BMG Labtech, Ortenberg, Germany).
The EE and number of drug molecules per particle was de-
termined as described above.
In Vitro Release Studies
The in vitro release of PFD was assessed through the dialysis
bag method. To that end, NPs containing PFD (NP-PFD), or
PFD and LA (NP-PFD/LA) were prepared at a 70:30 PEG-
PLA to PLGAmass ratio and purified as described above. An
initial PFD and LA mass of 2 mg and 4.5 mg, respectively,
were used. The samples were adjusted to a final volume of
2 mL (60 mg/mL NPs) and placed in a 3.5-5 kDa molecular
weight cut off Spectrum™ Spectra/Por™ 3 RC Dialysis
Membrane (Spectrum Laboratories, Inc., Rancho
Dominguez, CA, USA). The dialysis membrane was intro-
duced in a 35 mL glass vial containing 27 mL of DPBS
(pH 7.3) under sink conditions. Vials were kept in a 37°C
shaking water bath and 0.5 mL samples were taken at differ-
ent time points and replaced with fresh pre-warmed buffer. As
a control, particles with no encapsulated drug (NPMeO), and
free drug (PFD, 2.2 mg) were used. The PFD concentration
was quantified at 300 nm using a FLUOStar Omega micro-
plate reader (BMG Labtech, Ortenberg, Germany).
Statistical Analysis
Statistical analysis was performed using GraphPad Prism
Software 6.0. Student’s t test (Fig. 3 and Fig. 5a) was employed
to evaluate statistical significance. Levels of statistical signifi-
cance and “n” numbers for each experiment are indicated in
the text and figure legends.
RESULTS AND DISCUSSION
Thermodynamic Considerations for PFD Encapsulation
A frequent approach to estimate the compatibility of a drug in
a polymer is the calculation of their thermodynamic interac-
tions. This approach has been used by several authors to select
the most suitable polymers for encapsulating a certain drug or
retroactively explain experimental outcomes (26,27,36–38).
Here, we assessed the thermodynamic miscibility of PFD
and LA with either PEG, PLA or PLGA to determine the
suitability of our particle system for the selected drug(s). As
depicted in Eq. 16, the thermodynamic miscibility of two sub-
stances is given by the free energy of mixing (ΔGM), where
ΔHMT and ΔSM are the enthalpy and entropy of mixing,
respectively. If the ΔGM is negative, the two substances are
considered mutually soluble.
ΔGM ¼ ΔHMT−TΔSM ð16Þ
The mixing enthalpy (ΔHM) per volume unit for each
polymer-drug can be used as an indicator for the miscibility
of two substances. It is given by Eq. 5 after Hildebrand (26).
For its determination the volume fractions and the solubility
parameters of the drug and polymer,Φ1 andΦ2 and δ1 and δ2
respectively, are considered.
The solubility parameters for some common drugs and
polymers are reported in the literature (22,23). Otherwise they
can be calculated after van Krevelen and Nijenhuis (24) using
Eq. 4 by combining the contribution of the partial solubility
parameters associated with the dispersion forces (δd), the polar
interactions (δp) and the hydrogen bonding components (δh).
The total- and partial solubility parameters of PFD, LA and
the particle-forming polymers are depicted in Table I.
The miscibility of two components is promoted when their
solubility parameters have similar values and thus, ΔHMT
tends to 0. Therefore, the differences among solubility param-
eters of drug and polymer (Δδ, Δδd, Δδp, and Δδh) can also be
used to predict miscibility (37) (Table II).
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However, as Liu et al. pointed out, Eq. 5 does only take into
consideration dispersion forces (27). As an alternative, they
proposed the determination of ΔHM taking into account all
forces of the interaction by using the partial solubility param-
eters, as depicted in Eq. 6.
The most frequently used indicator to predict the miscibil-
ity of drug molecules with different polymers is the Flory-
Huggins interaction parameter (χsp) (8). It is given by the
Hildebrand-Scatchard equation (Eq. 7), which takes into ac-
count the total solubility parameters (δ) of the drug and poly-
mer in combination with themolar volume of the drug (Vdrug).
A complete miscibility is achieved when χsp is <0.5 (24) which
requires a very near match of both solubility parameters of
drug and polymer. The closer the χsp is to zero, the more
favorable interactions between the two components, and thus
the better compatibility of drug and polymer.
With the determined solubility parameters (δ, δd, δp, and
δh) (Table I) and their differences (Δδ, Δδd, Δδp, and Δδh)
(Table II), we calculated the mixing enthalpy (ΔHMT or
ΔHM), and χsp in order to predict the miscibility of our drugs
with the particle system (Fig. 2).
Comparing the total solubility parameters (δ) (Table I), it is
evident that all substances (drugs and polymers alike) have
very similar values ranging between 22 and 25 MPa1/2. This
indicates a very good match for the selected drug and poly-
mers, which is confirmed by the values of ΔHMT and ΔHM of
the PFD- or LA-polymer mixtures (Fig. 2). As pointed out by
Liu et al. (27), the absolute values forΔHMT andΔHMdiffered.
Furthermore, for the case of LA, a complete opposite tenden-
cy was seen (Fig. 2b). TheΔHMT predicted a highermiscibility
for PEG > PLGA > PLA, whereas the ΔHM anticipated a
better miscibility with PLA> PEG> PLGA. Nevertheless, the
enthalpy values for all mixtures were very close to zero pre-
dicting good miscibility from a thermodynamic point of view.
As the most common used parameter to predict drug-
polymer compatibility is the χsp, we also compared these val-
ues for the polymers composing our NPs. As depicted in Fig.
2c, the χsp values predict total miscibility of PFD with all the
polymers forming the particle with a predilection to PEG >
PLGA > PLA. However, for LA it indicates low miscibility
with PLGA and PLA, as χsp < 0.5 only for PEG, disagreeing
with the other estimated parameters. Overall, as suggested
previously by other authors (27), the different parameters pre-
dicting drug-polymer miscibility varied in terms of the poly-
mer which showed the highest miscibility. Nevertheless, ex-
cept the χsp for the LA-PLA or LA-PLGA mixture, all the
obtained values indicated thermodynamically favorable mis-
cibility. In general, the highest miscibility for PFD is predicted
to be with PEG, followed by PLGA and PLA (Fig. S1A and
Table I Partial and Total Solubility Parameters for the Drugs (PFD and LA)
and the Particle-Assembling Polymers
Component δd δp δh δ
PFD* 20.5 9.4 7.7 23.8
LA* 22.9 2.9 10.2 25.2
PEG#, (22) 20.3 9.6 6.0 24.0
PLA#, (22) 19.8 4.0 6.7 22.0
PLGA#, (23) 17.4 9.1 10.5 22.3
Obtained from literature#, calculated*
Table II Calculated Differences Between the Solubility Parameters or
Polarity of PFD or LA and the Particle-Forming Polymers
Particle component PFD LA
Δδd Δδp Δδh Δδt Δδd Δδp Δδh Δδt
PEG 0.2 - 0.2 1.7 - 0.2 2.6 - 6.7 4,2 1.2
PLA 0.7 5.4 1.0 1.8 3.1 - 1.1 3.5 3.2
PLGA 3.1 0.3 - 2.8 1.5 5.5 - 6.2 - 0.3 2.9
Fig. 2 Prediction of the drug-polymer miscibility. Mixing enthalpy of the
particle-assembling polymers and (a) PFD or (b) LA. (c) Flory-Huggins inter-
action parameter.
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Table SI). For LA the same trend in miscibility is to be
expected (Fig. S1B and Table SI).
As all determined parameters unanimously predict that
PFD is very compatible with all the particle-forming polymers,
we determined that the block copolymer PEG-PLA/PLGA
particle system is an appropriate candidate for its
encapsulation.
Influence of the Nanoprecipitation Technique on PFD
Loading
In order to experimentally investigate the encapsulation of
PFD in PEG-PLA/PLGA block copolymer NPs, we evaluat-
ed two different manufacturing techniques, bulk or MF nano-
precipitation (Fig. 3). To that end, PFD-polymer mixtures in
ACN were precipitated into a water phase, either manually or
with the assistance of a microfluidic device. The initial PFD
addition was varied to determine its influence on the drug
loading. The resulting particles were homogenous in terms
of size with narrow polydispersity indexes (PDI) (Fig. 3a) inde-
pendent of the amount of drug added to the formulation. As
frequently observed, MF manufacturing rendered particles
about 15 nm smaller (~ 50 nm) compared to bulk nanopreci-
pitated particles (~ 65 nm). This is due to the fact that the MF
mixing is faster than the time the particles need to nucleate,
which does not occur during bulk nanoprecipitation (39).
For both methods an increase in initial drug concentrations
reduced the EE (Fig. 3b), which can be partially explained by an
increase in mixing enthalpy with increasing volume fractions of
drug (Fig. S2). Interestingly, MF manufacturing achieved signif-
icantly higher EE, a phenomenon also described by other
authors (40,41). As an additional advantage, MF preparation
allows for a precise control over the manufacturing parameters,
such as the TFR (Fig. S3) and the FRR (Fig. S4) which, in turn,
permit drug loading optimization and a decrease in batch to
batch variations. Furthermore, the resulting particles have the
ideal size (~ 50 nm) for optimal NP-cell interaction (42) (Fig. S5).
Despite the decrease in efficiency of the process with higher
PFD amounts, the LC (Fig. 3c) and number of drug molecules
per particle (Fig. 3d) increased with larger initial PFD addi-
tions. This is frequent for particles entrapping the drug during
NP preparation (39), and is probably promoted in this partic-
ular case by the water solubility of PFD (~ 2 mg/mL).
Interestingly, both methods achieved a comparable number
of PFD molecules per particle, which is probably due to a
larger number of smaller particles being produced by MF
compared to bulk nanoprecipitation.
However, the low number of drug molecules that were
being incorporated into the particle system (under 1000
molecules per NP) was quite surprising, considering the
high predicted miscibility of PFD with the particle-
forming polymers (Fig. 2). By those calculations, PFD dis-
played a very high compatibility with PEG. Therefore,
part of the drug may end up in the particle’s shell.
However, during NP purification, this non-core-bound
drug is washed out through the several purification steps,
promoted by the water solubility of PFD, causing a lower
than expected EE.
Fig. 3 PFD encapsulation in block
copolymer NPs through bulk and
MF nanoprecipitation. Particle
characterization in terms of (a) size
and PDI, (b) Encapsulation
Efficiency (EE) (c) Loading Capacity
(LC) and (d) number of PFD mol-
ecules per particle. Results are
shown as mean± SD of at least
n=3 measurements. Levels of
statistical significance are indicated as
*p≤ 0.005, ***p≤ 0.001, and
****p≤ 0.0001.
Pharm Res           (2020) 37:59 Page 7 of 11    59 
Overall, we could demonstrate that PFD encapsulation in
block copolymer NPs is feasible by nanoprecipitation.
Comparing both manufacturing techniques, it is apparent
that MF is superior. Not only did it lead to a significantly
higher EE than bulk nanoprecipitation, but this could be fur-
ther enhanced up to 40% by adjusting the manufacturing
parameters (Fig. S3 and S4). More so, a higher cellular uptake
was achieved by MF-nanoprecipitated particles (Fig. S5)
which is highly relevant for in vitro and in vivo applications.
Spatial Limits on the Drug Encapsulation
Due to the low number of PFD molecules being incorporated
in our particles (Fig. 3), despite the high predicted miscibility
with the selected polymers, we decided to estimate the number
of drug molecules that would actually fit inside a single par-
ticle’s core (Fig. 4). For our determination we considered a
particle structure as depicted in Fig. 4a, where the PEG com-
poses the shell, the PLGA forms the particle core, and the PLA
is located at the core-shell interface. Given that after NPman-
ufacturing, the particles are purified from drug that is free or
entangled in the PEG shell through various washing and cen-
trifugation steps, we considered that the particle-bound drug
would mostly be located in the PLGA core. We speculated
that the spatial constriction given by the core size would de-
termine the number of PFDmolecules that can be fitted inside
the particle.
To determine the size of the core, the length of the PEG
brush was calculated and subtracted from the overall particle
diameter (~ 65 nm). To that end, we firstly determined the
conformation of the PEG shell on the particle corona. For our
NPs prepared at a 70:30 PEG-PLA to PLGA mass ratio, the
PEG assumes an extended brush conformation. This corre-
sponds to a length of approximatively 30 nm (for a PEGwith a
molecular weight of ~ 4800 Da). This would leave a particle
core of about 5 nm in diameter, which would allow for the
encapsulation of about 200 PFD molecules per NP, assuming
spherical shapes and 90% packing efficiency. It needs to be
noted that this calculation does not take into consideration the
space occupied by the core-forming PLGA itself. However,
the value is in the same size-range of that was experimentally
determined (Fig. 3).
Therefore, we hypothesized that the number of encapsu-
lated molecules per particle could be improved by increasing
the size of the PLGA core. To confirm these assumptions,
particles with an increase in PLGA mass ratio were prepared.
From the initial PEG-PLA to PLGA 70:30 mass ratio, we
raised the PLGA fraction to 60:40, 50:50 and 60:60. As
expected, the NPs increase in size in a linear manner from
60 to 120 nm (Fig. 4b). However, for all the formulations the
PEG assumed a brush conformation (Table SII), indicating
that the size increase was core-derived (Fig. S6). More impor-
tantly, the number of PFD molecules per particle increased
exponentially (Fig. 4c), therefore confirming our theory that
there is a spatial restriction for drug loading in a particle.
Co-Encapsulation of LA and PFD in Block Copolymer
NPs
Even though increasing the size of the PLGA core dramati-
cally enhanced the number of PFD molecules per NP, for
certain applications this may not be a feasible option. More
so, the number of PFD molecules per NP did not reach the
extent that would be expected from the linear size increase
(Fig. S7). This can be explained, on the one hand, by the
volume that the PLGA takes up in the core by itself and which
Fig. 4 Core volume-dependent PFD encapsulation. (a) structure of a block
copolymer NP. d(NP): particle diameter; r(PEG): PEG-brush radius; d(core):
particle core diameter. (b) NP size and (c) PFD molecules per NP with
increasing PLGA mass fraction. Results are shown as mean± SD of at least
n = 3 measurements. Data in (b) and (c) are fitted with a linear and an
exponential growth equation, respectively.
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was not considered for the calculations. On the other hand,
the high affinity of PFD to PEG may limit its core localization
and promote a partial distribution among the NP shell. This
PEG-associated PFD is removed during particle purification
due to water solubility of the drug (2 mg/mL). However, a
PEG shell is highly necessary for the in vivo applications of NPs,
as it reduces protein adsorption (29,34) and increases their
blood residence (43).
As an alternative approach, we hypothesized that inclusion of
an additional drugmolecule, also compatible with PEG but high-
ly water insoluble, would increase the number of PFD molecules
per NP by limiting the PFD diffusion to the aqueous phase.
As a candidate we selected LA. It has a very poor water
solubility (0.2 mg/mL), which is 10-times lower than for PFD
(2 mg/mL). Additionally, as determined by the miscibility
prediction (Fig. 2), it is compatible with the particle forming
polymers, especially with PEG.More so, at a therapeutic level
it may show complementary effects to PFD as they both dem-
onstrate positive antioxidative effects in doxorubicin-induced
cardiac and renal toxicity (44) and oxidative liver damage (45).
To test our hypothesis, we prepared NPs encapsulating both
PFD and LA (Fig. 5). Initially we combined different PFD and
LA ratios and examined the EE. As depicted in Fig. 5a, a LA
molar excess significantly increased the EE from 20% to 40%.
We then maintained a constant PFD concentration and varied
the formulation’s LA content. Interestingly, an exponential
increase/decrease in PFD molecules per NP was observed as
LA content was increased/lowered (up to 25,000 PFD mole-
cules/NP) (Fig. 5b). When comparing the size of particles only
incorporating LA with the ones encapsulating LA and PFD,
there was only a 10 nm size difference (Fig. 5c). Furthermore,
the number of PFD molecules per NP reached with increasing
LA addition could not be achieved by just increasing the initial
PFD added to the formulations (Fig. 5d), which reached a max-
imum of about 1000 molecules per particle (dashed line in Fig.
5b and d). This rising number of PFD molecules per NP can be
explained by a decrease in mixing enthalpy with increasing
amounts of LA, which may promote the miscibility of PFD with
the particle-forming polymers (Fig. S8). Additionally, the lower
water solubility of LA and its interaction with PFDmay promote
a stronger particle binding of the latter. This is reinforced by the
fact that the single encapsulation of LA, reaches a higher number
of molecules per NP (Fig. S9) compared to the individual PFD
encapsulation.
Fig. 5 Co-encapsulation of LA and
PFD in block copolymer NPs. (a)
NPs prepared with varying PFD to
LA molar ratios. (b) PFD molecules
per particle and (c) size of NPs
prepared with increasing LA
amounts. (d) Maximum number of
PFD molecules per particle at
increasing initial PFD amounts.
Results are shown as mean± SD of
at least n = 3 measurements.
Levels of statistical significance are
indicated as **p≤ 0.01 and *p≤
0.05 compared to NPs without LA,
n.s.: non-significant. Data in (b) are
fitted with an exponential growth
equation. Data in (c) and (d) are
fitted with a saturation curve.
Fig. 6 Release profile of PFD from block copolymer NPs. PFD: Free drug;
NP-PFD: PFD-loaded NPs; NP-PFD/LA: PFD- and LA-loaded NPs;
NPMeO: control, drug-free NPs. Results are shown as mean± SD of at least
n=3 measurements.
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However, the co-encapsulation of an additional drug mole-
cule can raise concerns about its interference with the release
profile of the original drug. Therefore, we investigated the PFD
in vitro release from the different NP formulations using the dial-
ysis bagmethod. To that end, NPs containing PFD (NP-PFD) or
PFD and LA (NP-PFD/LA) were compared. As controls, the
release profiles under the same conditions of drug-free particles
(NPMeO) and free drug (PFD) were evaluated. As depicted in
Fig. 6, after 1 h all of the free-drug was released from the dialysis
membrane. At that time point, about 70% of the PFD was
released from the NPs. The remaining 30% of the particle-
bound drug was released very slowly over the course of the next
5 h. This fast release is probably due to the large surface area to
volume ratio resulting from the small particle size. Additionally,
the water-solubility of PFDmay boost this effect. However, these
results are in line with the release of other hydrophilic drugs
prepared through nanoprecipitation, such as procaine hydro-
chloride from PLGA NPs (4). Comparing the release profiles of
NP-PFD and NP-PFD/LA it becomes apparent that both par-
ticle formulations show the same release curve. Therefore, we
can conclude that the LA incorporation has no detrimental
effects on the PFD release (Fig. 6).
CONCLUSION
In this study we systematically examined the encapsulation of
PFD, a water-soluble drug lacking ionizable groups, in block
copolymer NPs through nanoprecipitation.We determined dif-
ferent thermodynamic parameters which predicted a goodmis-
cibility of the drug with the particle-forming polymers (PEG,
PLA and PLGA) (Fig. 2). We showed that the calculation of
different parameters yielded slight differences among their pre-
dictions (Fig. S1), which is in agreement with previous studies.
More so, even though useful for selecting appropriate polymers
for the drug encapsulation, they cannot be exclusively consid-
ered. We demonstrate that spatial constrictions regarding the
particle’s core size can also limit the number of molecules that
can be encapsulated in polymer NPs (Fig. 4) and bymodulating
them the number of encapsulated molecules can be increased.
We experimentally assessed the EE, LC and number of encap-
sulated drug molecules per particle using two common nano-
precipitation techniques (Fig. 3). Among them, we were able to
demonstrate that MF manufacturing achieves significantly
higher drug loading with the additional benefit of precise ad-
justment of the process parameters (Fig. S3 and S4) and en-
hanced NP-cell interactions (Fig. S5).
Lastly, we demonstrated how the encapsulation of an ad-
ditional drug, LA, with similar polymer miscibility but lower
water solubility is able to exponentially increase the number of
PFD molecules per NP (Fig. 5) without affecting the drug’s
release profile (Fig. 6).
Overall our study demonstrates that the encapsulation of a
water-soluble drug without ionizable groups is feasible when
taking into consideration and adjusting the limits due to size
constrictions and appropriately selecting the manufacturing
method (MF vs bulk nanoprecipitation). More so, by consid-
ering the co-encapsulation of an additional appropriate mol-
ecule an additional increase in drug loading can be achieved.
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